Ipamorelin + Tesamorelin

Ipamorelin + Tesamorelin is a vendor blend that pairs two growth-hormone-axis peptides: tesamorelin, a stabilized analog of growth-hormone-releasing hormone (GHRH), and ipamorelin, a selective secretagogue that acts on the ghrelin receptor. The pairing is positioned conceptually as targeting complementary points in the same signaling system.

Tesamorelin alone is an approved medicine in some settings, but this specific blend is not an FDA-approved product. It appears in experimental and wellness-oriented contexts rather than in mainstream endocrine guidelines.

The rationale for the blend rests on combining two distinct mechanisms:

• Tesamorelin acts at GHRH receptors in the pituitary, a stabilized analog designed to promote physiologic growth-hormone release

• Ipamorelin stimulates the growth-hormone secretagogue receptor (GHSR), selectively supporting pulsatile GH output with relatively little effect on prolactin or cortisol

The hypothesis is that acting on both pathways at once could produce a complementary signal. Whether this offers meaningful advantages over either agent alone in specific individuals is an area of discussion rather than settled evidence.

Tesamorelin has a recognized approved use in HIV-associated lipodystrophy, where it has been studied for reducing excess visceral fat. Ipamorelin, by contrast, is not an approved medicine. The combined blend has no approved indication of its own.

Because the pairing is a vendor product rather than a labeled therapy, any consideration of it should be grounded in the difference between tesamorelin's specific approved context and the broader, less-supported wellness narratives that surround combination products.

Neither component relies on a catch-all clause. Sub-section S2.2.4 of the WADA Prohibited List lists "growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin)" in one bullet and "growth hormone secretagogues (GHS) and their mimetics [e.g. anamorelin, capromorelin, ibutamoren (MK-677), ipamorelin, lenomorelin (ghrelin), macimorelin and tabimorelin]" in the next. Both are non-Specified Substances, so the default first-offence sanction is four years.

The combination raises exposure rather than splitting it. Ipamorelin has a validated urine method: after nasal administration, the parent compound is metabolised intensively and the Ipamorelin (1-4) free acid remains detectable after the parent has cleared (Semenistaya et al., Drug Test Anal 2015). Tesamorelin, meanwhile, is an approved medicine, so a laboratory finding is unambiguous — there is no "unapproved research compound, therefore untested" argument available.

A therapeutic use exemption for tesamorelin exists in principle for its labelled indication (HIV-associated lipodystrophy), but it would not extend to the ipamorelin component, and USADA has noted for the closely analogous case of sermorelin that "it is highly unlikely a TUE would be approved… as it is not a first-line treatment" (USADA athlete guidance). For a tested athlete, a blend of the two is two violations in one vial.

Sanctions built on exactly this kind of stack are on the record: Vahe Aivazian, a masters cyclist, accepted a four-year USADA sanction beginning 7 April 2021 for possession and use of ten substances including ipamorelin, CJC-1295, GHRP-6, somatropin and IGF-1 (USADA announcement). No positive test for any individual peptide was required.

Reported or theoretical effects include injection-site reactions, flushing, headache, changes in sleep or appetite, and broader GH/IGF-1-related concerns such as effects on glucose handling, fluid balance, and tissue growth over time.

Because evidence on the combined blend is more limited than for tesamorelin's studied indication, risk-benefit assessment requires particular caution and is best handled by clinicians familiar with GH physiology.

The blend combines a GHRH analog and a secretagogue that act at different receptors, which is the conceptual basis for pairing them. Tesamorelin is a stabilized GHRH analog, and ipamorelin is short-acting and selective.

This information summarizes conceptual pharmacology and does not constitute medical advice.

The two halves of this blend are not comparable objects, and the difference is the most useful thing to know about the product:

• Tesamorelin is a prescription medicine. Two products are marketed — EGRIFTA SV and EGRIFTA WR — for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy, at 1.4 mg and 1.28 mg daily respectively, with product-specific vial strengths and reconstitution instructions and a label stating they are not substitutable for one another (EGRIFTA SV prescribing information, DailyMed).

• Ipamorelin has never been approved anywhere for anything. Its clinical development stopped after a phase 2 trial in postoperative ileus missed its primary endpoint (Beck et al. 2014).

If a label cannot legally distinguish two versions of tesamorelin from each other, a compounded vial mixing tesamorelin with a second, unapproved peptide has no meaningful specification at all — no established content, no ratio, no stability data for the mixture. Related pairings sold on the same rationale include CJC-1295 + ipamorelin, which substitutes a different GHRH analogue and is equally untested as a combination.

There are no dedicated clinical trials of this specific blend. The available evidence is extrapolated from the two components: tesamorelin has a studied, approved use in HIV-associated lipodystrophy, while ipamorelin has been examined mainly as a selective secretagogue in earlier-stage research.

Because combining the agents has not been formally validated, the pairing is best viewed as a conceptual extension of single-agent data rather than an established therapy. High-level overviews like this should not be used to justify specific regimens.

For deeper dives on this peptide, see:

• Ipamorelin + Tesamorelin benefits and areas of interest
• Ipamorelin + Tesamorelin side effects and safety context
• Ipamorelin + Tesamorelin dosing concepts (educational)
• Ipamorelin + Tesamorelin research and evidence overview

Has this blend ever been studied? No. There is no published trial of tesamorelin and ipamorelin given together, and ClinicalTrials.gov lists three ipamorelin studies, none of which involves tesamorelin, and no study of the pairing under any name. The blend has no dedicated safety data, no pharmacokinetic characterisation, and no established ratio. That is the headline; everything below is component-level.

Which half is a real medicine, and for what? Tesamorelin, and for one narrowly defined indication: reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. In the pooled phase 3 analysis of 806 adults on 2 mg daily, visceral adipose tissue fell 24 cm² versus a 2 cm² increase on placebo at week 26 — a 15.4% treatment effect (Falutz et al., J Clin Endocrinol Metab 2010). Ipamorelin has no approved indication anywhere.

Does the blend deliver the tesamorelin result? Nothing supports that. The trial figure above came from 2 mg daily of a specific, since-replaced product; the currently approved doses are 1.4 mg (EGRIFTA SV) and 1.28 mg (EGRIFTA WR) daily, and the label states the two are not substitutable for each other (DailyMed). A blended vial matches neither, in a population that resembles neither.

If the visceral fat does come off, does it stay off? No. In the 404-patient trial, patients re-randomised from tesamorelin to placebo at six months rapidly lost the visceral fat improvement they had gained (Falutz et al., J Acquir Immune Defic Syndr 2010). Tesamorelin is an ongoing therapy, not a course with a durable result — which is a different proposition from how combination "GH stacks" are usually described.

What has the FDA said about the ipamorelin half? Two things, both negative. In October 2024 an FDA advisory committee voted 0 to 12 with one abstention against allowing ipamorelin on the 503A list of substances compounding pharmacies may use, citing a lack of information supporting safety and efficacy (PCAC minutes). Separately, its entry on FDA's bulk drug substances page cites immunogenicity risk from aggregation, unnatural amino acids complicating characterisation, and "serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility" (FDA).

Does pairing a GHRH analogue with a secretagogue actually add anything? It is a reasonable-sounding hypothesis — two receptors, one hormone axis — with no controlled human test behind it. The same argument is used for every GHRH-plus-secretagogue pairing sold, and none of those combinations has a published trial either. Meanwhile the component with the strongest evidence, tesamorelin, was studied alone.

Does tesamorelin's approval make the blend safer? No, and it arguably works the other way. Tesamorelin's own label carries a glucose-intolerance warning (EGRIFTA SV prescribing information), growth hormone opposes insulin by mechanism, and adding a second growth-hormone secretagogue does not reduce that exposure. An approved component inside an unapproved mixture is still an unapproved mixture — and it removes the ability to adjust either component independently.